Related Experiment Video

Updated: Jun 16, 2026

Transcranial Direct Current Stimulation (tDCS) for Memory Enhancement
10:37

Transcranial Direct Current Stimulation (tDCS) for Memory Enhancement

Published on: September 18, 2021

Bridging neurocognitive aging and disease modification: targeting functional mechanisms of memory impairment

M Gallagher1, A Bakker, M A Yassa

  • 1Department of Psychological and Brain Science, Johns Hopkins University, Baltimore, MD 21218, USA. michela@jhu.edu

Current Alzheimer Research
|January 22, 2010
PubMed

Insights

As people age, Alzheimer's disease risk increases. Researchers identified a novel approach targeting age-related memory impairment in the medial temporal lobe to potentially restore memory and slow Alzheimer's progression.

Area of Science:

  • Neuroscience
  • Gerontology
  • Pathology

Background:

  • Alzheimer's disease (AD) risk significantly increases with age.
  • Amnestic mild cognitive impairment (aMCI) represents an early stage with memory loss exceeding age-expected decline, offering a key window for intervention.
  • Understanding age-related memory impairment is crucial for developing effective AD treatments.

Purpose of the Study:

  • To discuss a basis for age-related memory impairment.
  • To explore a novel intervention point for restoring memory function.
  • To investigate potential benefits in slowing Alzheimer's disease progression.

Main Methods:

  • Review of existing research on age-related memory impairment.
  • Discussion of findings from animal models.
  • Analysis of recent discoveries in the human medial temporal lobe system.

Main Results:

  • A specific basis for age-related memory impairment has been identified.
  • This basis was first observed in animal models and subsequently in the human medial temporal lobe.
  • This discovery presents a novel target for therapeutic intervention.

Conclusions:

  • Targeting the identified basis of age-related memory impairment offers a new strategy for memory restoration.
  • Intervention at this level may provide a benefit in slowing the progression of Alzheimer's disease.
  • Further research into this novel entry point is warranted for AD treatment development.

More Related Videos

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...